Squarepoint
XENE icon

Squarepoint’s Xenon Pharmaceuticals XENE Stock Holding History

Squarepoint’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.81M Buy
+112,869
New +$6.27M 0.01% 1352
2025
Q1 		– Sell
-6,554
Closed -$257K – 5532
2024
Q4 		$257K Sell
6,554
-950
-13% -$39.3K ﹤0.01% 4273
2024
Q3 		$295K Buy
+7,504
New +$303K ﹤0.01% 3458
2024
Q1 		– Sell
-8,253
Closed -$380K – 4687
2023
Q4 		$380K Buy
+8,253
New +$292K ﹤0.01% 3203
2022
Q4 		– Sell
-10,605
Closed -$383K – 3653
2022
Q3 		$383K Buy
10,605
+3,555
+50% +$128K ﹤0.01% 2339
2022
Q2 		$214K Buy
+7,050
New +$213K ﹤0.01% 2441
2022
Q1 		– Sell
-11,014
Closed -$344K – 3615
2021
Q4 		$344K Buy
+11,014
New +$329K ﹤0.01% 2376
2020
Q3 		– Sell
-24,321
Closed -$305K – 2886
2020
Q2 		$305K Buy
24,321
+4,281
+21% +$54.5K ﹤0.01% 1596
2020
Q1 		$227K Sell
20,040
-12,037
-38% -$171K 0.01% 1425
2019
Q4 		$421K Sell
32,077
-55,023
-63% -$579K ﹤0.01% 1865
2019
Q3 		$785K Sell
87,100
-5,890
-6% -$55.7K 0.01% 1384
2019
Q2 		$917K Buy
92,990
+60,863
+189% +$582K 0.01% 1312
2019
Q1 		$326K Buy
+32,127
New +$272K ﹤0.01% 1730

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Squarepoint's XENE Position: Q2 2026 in Review

Squarepoint opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 112,869 shares worth $6.81M. The stake represents 0.01% of the portfolio and ranks #1352 among its holdings. This is a return to the name: Squarepoint previously reported a position in XENE as recently as Q4 2024.

Squarepoint first reported a position in XENE in Q1 2019 and has held it in 13 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Squarepoint held 112,869 shares of Xenon Pharmaceuticals worth $6.81M as of Q2 2026.
  • Xenon Pharmaceuticals was a new Squarepoint position in Q2 2026.
  • Xenon Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1352 holding.
  • Squarepoint first reported a position in Xenon Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.